520 search results for “medical drug violence” in the Staff website
-
Interdisciplinary minor ’Violence Studies’: ‘It felt like we were going to fight a group of people’
The interdisciplinary, English-taught minor ‘Violence Studies’ looks at violence from very diverse scientific perspectives. What are the benefits from this approach? Students and lecturers evaluate: ‘This minor’s a goldmine’.
-
Dutch people are understanding the term ‘violence’ to mean more and more
When do we say violence was used in an incident? The answer may seem obvious at first. But interim results from a study by Jolien van Breen show that Dutch people are labelling events in increasingly broad contexts as violent.
-
Dennis Bos
Faculty of Humanities
d.bos@hum.leidenuniv.nl | +31 71 527 2722
-
May Tamimová
Faculty Governance and Global Affairs
m.tamimova@fgga.leidenuniv.nl | +31 70 800 8206
-
Lenneke Alink
Faculteit der Sociale Wetenschappen
alinklra@fsw.leidenuniv.nl | +31 71 527 3432
-
Come to the Medical Delta Societies introduction meetings
Research
-
Review paper on the potential impact drug-metabolizing enzymes on brain exposure
PhD candidate Mengxu Zhang (Division of Systems Pharmacology and Pharmacy) published a comprehensive and important review on “The potential impact of CYP and UGT drug-metabolizing enzymes on brain target site drug exposure” in Drug Metabolism Reviews.
-
Growth Fund invests many millions in faster and more sustainable (cancer) drug development
On 14 April, the National Growth Fund awarded million euros in grants to two consortia in which Leiden's science faculty is involved. Pharma-NL will receive 80 million euros and Oncode-PACT 325 million euros. Pharma-NL wants to make medicines available to the patient faster and more sustainably. Oncode-PACT…
-
From lab discovery to a new drug: the Venture Challenge makes it possible
A breakthrough from the PhD research of medical chemist Elmer Maurits may help patients with autoimmune diseases and blood cancer in the future. But bringing a discovery from the lab to the clinic is not so easily done. Thanks to NWO's Venture Challenge, Maurits and his team will receive ten weeks of…
-
Universiteit Leiden Announce Collaboration to Develop Advanced Polyaminoacid Drug Delivery Systems
Polypeptide Therapeutic Solutions (PTS), a leader in the design, development and custom manufacturing of polyamino-acid based delivery systems for therapeutic drugs and the Leiden Academic Centre for Drug Research (LACDR) today announced a research collaboration to develop advanced drug delivery systems…
-
Andries Hiskes
Faculty of Humanities
a.r.hiskes@hum.leidenuniv.nl | +31 71 527 2727
-
Fenneke Sysling
Faculty of Humanities
f.h.sysling@hum.leidenuniv.nl | +31 71 527 2737
-
S. Valdez
Faculty of Humanities
s.valdez@hum.leidenuniv.nl | +31 71 527 2727
-
Annemarie Samuels
Faculteit der Sociale Wetenschappen
a.samuels@fsw.leidenuniv.nl | +31 71 527 1724
-
Mirjam Sombroek-van Doorm
Faculteit Rechtsgeleerdheid
m.p.sombroek@law.leidenuniv.nl | +31 71 527 2727
-
Eisma is the spokesperson for the government commissioner on sexual violence
It is one of the most talked-about subjects right now: how do we eradicate sexual harassment and violence? Alumnus Femke Eisma is the spokesperson for Mariëtte Hamer, the government commissioner tasked with tackling this persistent social problem. Eisma studied the Dutch language at Leiden. How is her…
-
Medical Delta professor Ariane Briegel: 'I love working with people from different backgrounds'
Multidrug-resistant pathogens and worldwide pandemics are increasing, making infectious diseases more prevalent. To develop new treatments, deeper knowledge of the interaction between bacteria and human cells is required. Ariane Briegel recently became a Medical Delta professor and studies such path…
-
Anthe Janssen
Science
a.p.a.janssen@lic.leidenuniv.nl | +31 71 527 4362
-
Joost Batenburg
Science
k.j.batenburg@liacs.leidenuniv.nl | +31 71 527 6985
-
Coen van Hasselt
Science
coen.vanhasselt@lacdr.leidenuniv.nl | +31 71 527 3266
-
From discovery to business: 'In the lab, we often don't realise that we are working to help an immense number of patients'
'It gave our team a big boost to hear that our work was valuable,' says medical chemist Elmer Maurits about the moment they won the Venture Challenge. With their company Iprotics, they want to develop a drug that can better treat patients with autoimmune diseases and blood cancers. 25,000 euros of prize…
-
Carlotta Rigotti
Faculteit Rechtsgeleerdheid
c.rigotti@law.leidenuniv.nl | +31 71 527 8838
-
Marina Calculli
Faculty of Humanities
m.calculli@hum.leidenuniv.nl | +31 71 527 2727
-
Renate Buisman
Faculteit der Sociale Wetenschappen
r.s.m.buisman@fsw.leidenuniv.nl | +31 71 527 3441
-
Joost Augusteijn
Faculty of Humanities
j.augusteijn@hum.leidenuniv.nl | +31 71 527 2763
-
Havar Solheim
Faculty of Humanities
h.a.s.solheim@hum.leidenuniv.nl | +31 71 527 5342
-
Jeanine de Roy van Zuijdewijn
Faculty Governance and Global Affairs
j.h.de.roy.van.zuijdewijn@fgga.leidenuniv.nl | +31 70 800 9328
-
Matthew Hoye
Faculty Governance and Global Affairs
j.m.hoye@fgga.leidenuniv.nl | +31 70 800 9506
-
Sarah Louise Carthy
Faculty Governance and Global Affairs
s.l.carthy@fgga.leidenuniv.nl | +31 70 800 9506
-
Ton Liefaard
Faculteit Rechtsgeleerdheid
t.liefaard@law.leidenuniv.nl | +31 71 527 2727
-
Skin researcher calls for multidisciplinary collaboration: ‘I want to pool expertise’
In dermatology, there should be a high level of multidisciplinary collaboration among institutes and specialists, Professor of Translational Dermatology, Robert Rissmann, will say in his inaugural lecture on 8 July. He is building an infrastructure that will put pre-clinical and clinical skin research…
-
Seeking new concepts to treat diseases
Scientific Director of the Leiden Academic Centre for Drug Research (LACDR) Hubertus Irth: ‘We test substances and look for new concepts for treating disease.’
-
for effective application of a new revolutionary cholesterol lowering drug resides in a 30 year old Leiden Patent
‘’ And then the world changed forever ,welcome to the future’’. These are the words that Kausik Ray (President of the European Atherosclerosis Society) spoke when the worldwide first dose of inclisiran, a novel SiRNA based cholesterol lowering agent, was administered at the Cardiology lipid clinic at…
-
Sebastian Pomplun
Science
s.j.pomplun@lacdr.leidenuniv.nl | +31 71 527 4651
-
Nina Eggens
Faculteit Rechtsgeleerdheid
n.eggens@law.leidenuniv.nl | +31 71 527 2727
-
Lison Laroche
Science
l.l.s.laroche@cml.leidenuniv.nl | +31 71 527 2727
-
RARE-NL: LUMC joins consortium to find treatments for rare diseases
RARE-NL, a new collaboration between university hospitals, hopes to find treatments for rare diseases. Professor Teun van Gelder is representing the LUMC in the initiative.
-
Bas ter Braak
Science
s.j.ter.braak@lacdr.leidenuniv.nl | +31 71 527 2727
-
Marije Niemeijer
Science
m.c.niemeijer@lacdr.leidenuniv.nl | +31 71 527 6105
-
Marcel Schaaf
Science
m.j.m.schaaf@biology.leidenuniv.nl | +31 71 527 4975
-
Thomas Hankemeier
Science
hankemeier@lacdr.leidenuniv.nl | +31 71 527 4226
-
Unacceptable behaviour
Leiden University aims to create a safe environment where everyone feels comfortable and no one experiences unacceptable behaviour. Should students experience this nevertheless, there are various resources that you can refer them to.
-
The molecular secrets of medicinal cannabis
Chronic pain, nausea or vomiting due to chemotherapy. If you suffer from such ailments, medicinal cannabis can be a godsend. Though a downside is that it can make patients high. Therefore, Leiden researchers from the Oncode Institute are investigating alternatives that do not make you high. In Nature…
-
Is a cancer pill a matter of time?
A cancer pill, preferably without severe side effects, is something we’d all welcome. Is it a matter of time before such a pill is a reality? We put this question to three Leiden researchers and asked how they themselves are contributing to new cancer treatments.
-
How Oncode-PACT is bringing new cancer medicines closer with 325 million in Growth Fund money
How can you ensure that more experimental drugs reach the finish line? At the moment, only one in twenty cancer drugs that are tested on humans makes it to the market. This is an enormous loss for patients and society. With a grant from the National Growth Fund, Oncode-PACT aims to efficiently select…
-
Steffen Brünle
Science
s.bruenle@lic.leidenuniv.nl | +31 71 527 4544
-
Babak Rezaeedaryakenari
Faculteit der Sociale Wetenschappen
s.rezaeedaryakenari@fsw.leidenuniv.nl | +31 70 800 3687
-
Bareez Majid
Faculty of Humanities
b.majid@hum.leidenuniv.nl | +31 71 527 5154
-
Vivian Kraaij
Faculteit der Sociale Wetenschappen
kraaij@fsw.leidenuniv.nl | +31 71 527 3736
-
To explore the drug space smarter: Artificial intelligence in drug design for G protein-coupled receptors
PhD defence